E. Voltz

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

L. Altucci, H. Gronemeyer, A. Lera, 2005, Nature Medicine.

Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056).

E. Voltz, R. Woessner, E. Legangneux, 2016, Clinical therapeutics.

P.371 Safety and efficacy findings in the first-in-human trial (FIH) of the oral splice modulator branaplam in type 1 spinal muscular atrophy (SMA): interim results

J. Praestgaard, E. Voltz, E. Bertini, 2017, Neuromuscular Disorders.

A new era of cancer therapy: cancer cell targeted therapies are coming of age.

H. Gronemeyer, E. Voltz, 2008, The international journal of biochemistry & cell biology.

Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine

W. Hahn, H. Gronemeyer, E. Voltz, 2011, Molecular Cancer Therapeutics.

Tumor suppressor IRF‐1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL

H. Gronemeyer, N. Clarke, E. Voltz, 2004, The EMBO journal.